What is he best known for?
The fields of study he is best known for:
- Dopamine
- Parkinson's disease
- Neurotransmitter
Jonathan M. Brotchie mostly deals with Parkinson's disease, Neuroscience, Dyskinesia, Levodopa and Dopamine.
His Parkinson's disease research incorporates themes from Dopaminergic and Endocrinology.
His research integrates issues of Disease, Parkinsonism and Subthalamic nucleus in his study of Neuroscience.
His research in Dyskinesia intersects with topics in Serotonergic and Pharmacology.
His biological study spans a wide range of topics, including NMDA receptor, Opioid receptor and Cannabinoid Receptor Agonists.
His study in Dopamine is interdisciplinary in nature, drawing from both Degeneration and 5-HT receptor.
His most cited work include:
- Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies (405 citations)
- Relationship between the Appearance of Symptoms and the Level of Nigrostriatal Degeneration in a Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease (402 citations)
- Levodopa-induced dyskinesias. (351 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Parkinson's disease, Dyskinesia, Neuroscience, Pharmacology and Dopamine.
His studies deal with areas such as Dopaminergic and Endocrinology as well as Parkinson's disease.
Jonathan M. Brotchie has researched Dyskinesia in several fields, including Levodopa, Parkinsonism and MPTP.
Jonathan M. Brotchie studies Neuroscience, focusing on Basal ganglia in particular.
His Pharmacology study combines topics from a wide range of disciplines, such as Receptor, Antagonist and Dihydroxyphenylalanine.
His Dopamine research incorporates themes from NMDA receptor and Opioid peptide.
He most often published in these fields:
- Parkinson's disease (46.85%)
- Dyskinesia (41.34%)
- Neuroscience (35.83%)
What were the highlights of his more recent work (between 2014-2021)?
- Parkinson's disease (46.85%)
- Pharmacology (35.43%)
- Neuroscience (35.83%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Parkinson's disease, Pharmacology, Neuroscience, Dyskinesia and Dopaminergic.
The Parkinson's disease study combines topics in areas such as Dopamine and Parkinsonism.
His Pharmacology research integrates issues from Peripheral blood mononuclear cell, Potency, Kinase and LRRK2.
His Neuroscience research is multidisciplinary, relying on both Pathophysiology and Disease.
The various areas that Jonathan M. Brotchie examines in his Dyskinesia study include Levodopa, Cognition and MPTP.
Endocrinology and Internal medicine are the main topics of his Dopaminergic study.
Between 2014 and 2021, his most popular works were:
- Animal models of [alpha]-synucleinopathy for Parkinson disease drug development (85 citations)
- α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era (71 citations)
- Management of impulse control disorders in Parkinson's disease: Controversies and future approaches (66 citations)
In his most recent research, the most cited papers focused on:
- Dopamine
- Neurotransmitter
- Internal medicine
Jonathan M. Brotchie spends much of his time researching Parkinson's disease, Dopaminergic, Neuroscience, Dopamine and Pharmacology.
His Parkinson's disease study frequently links to other fields, such as Neurodegeneration.
His Neuroscience study frequently links to related topics such as Disease.
In his work, Anatomy and Nigrostriatal pathway is strongly intertwined with Macaque, which is a subfield of Dopamine.
His Pharmacology research incorporates elements of Neurotoxicity, Trehalose, Dyskinesia, Neurochemical and Reuptake inhibitor.
His research investigates the connection with Dyskinesia and areas like MPTP which intersect with concerns in Receptor antagonist.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
